三维组织药敏法在肿瘤个体化精准医疗中的应用

doi:10.11904/j.issn.1002-3070.2018.03.019

Abstract

Abstract: At present,most chemotherapy schemes for malignant tumors use the standard chemotherapy regimen recommended by the National Comprehensive Cancer Network(NCCN)clinical practice guidelines,because they ignore the inherent heterogeneity of the tumor,resulting in low efficiency,high toxic and side effects,and high costs issues.Therefore,the realization of “individualized and accurate medical care” for cancer is a general trend.The sensitivity screening of chemotherapy drugs for cancer patients to achieve individualized precise drug delivery is one of the main contents of “individualized precision medicine”.The three-dimensional histoculture drug response assay(HDRA)is a method for detecting drug sensitivity after in vitro cultivation of active tumor tissue blocks obtained by surgical resection or biopsy.It not only has a short experimental cycle,but it also maintains the tumor tissue structure,heterogeneity and micro-environment,which have high clinical practice consistency,and it is a relatively promising technique for detecting drug susceptibility.Therefore,this article reviews the development history,clinical application and the future development trend of HDRA.

Key words: HDRA, Malignant tumor, Individualized precision medicine, Chemotherapeutics

CLC Number:

R73-35+1

JI Qiao, CHEN Li, HE Yuanqiao. Application of drug sensitivity from three-dimensional tissue in individualized precision medical treatment for tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 280-284.

References

1 Chen W,Zheng R,Zhang S,et al.Cancer incidence and mortality in China in 2013:an analysis based on urbanization level[J].Chin J Cancer Res,2017,29(1):1-10.
2 Al-batran SE,Hartmann JT,Hoffhein ZR,et al.Biweekly fluorouracil,leucovorin,oxaliplatin,and docetaxel(FLOT)for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction:a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie[J].Ann Oncology,2008,19(11):1882-1887.
3 Matchettk KB,Lynamlennon N,Watson RW,et al.Advances in precision medicine:tailoring individualized therapies[J].Cancers,2017,9(11):146.
4 Topol EJ.Individualized medicine from prewomb to tomb[J].Cell,2014,157(1):241-253.
5 Collins FS,Harmus H.A new initiative on precision medicine[J].New Engl J Med,2015,372(9):793-795.
6 Hoffman RM.In vitro sensitivity assays in cancer:A review,analysis,and prognosis[J].J Clin Lab Anal,2010,5(2):133-143.
7 Schrag D,Garewal HS,Burstein HJ,et al.American society of clinical oncology technology assessment:chemotherapy sensitivity and resistance assays[J].J Clin Oncol,2004,22(17):3631-3638.
8 Samson DJ,Seidenfeld J,Ziegler K,et al.Chemotherapy sensitivity and resistance assays:a systematic review[J].J Clin Oncol,2004,22(17):3618-3630.
9 Gwak HS,Park HJ,Yoo H,et al.Chemotherapy for malignant gliomas based on histoculture drug response assay:a pilot study[J].J Korean Neurosurg Soc,2011,50(5):426-433.
10 Freeman AE,Hoffman RM.In vivo-like growth of human tumors in vitro[J].Proc Natl Acad Sci U S A,1986,83(8):2694-2698.
11 Vescio RA,Redfern CH,Nelson TJ,et al.In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture[J].Proc Natl Acad Sci U S A,1987,84(14):5029-5033.
12 Uruno T,Masaki C,Akaishi J,et al.Chemosensitivity of anaplastic thyroid cancer based on a histoculture drug response assay[J].Int J Endocrinol,2015,2015:967286.
13 Fujita Y,Hiramatsu M,Kawai M,et al.Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer[J].Oncol Rep,2009,21(2):499.
14 Yoon YS,Kim CW,Roh SA,et al.Applicability of histoculture drug response assays in colorectal cancer chemotherapy[J].Anticancer Res,2012,32(8):3581-35816.
15 Hoffman RM.The three-dimensional question:can clinically relevant tumor drug resistance be measured in vitro?[J].Cancer Metast Rev,1994,13(2):169-173.
16 Carrel A.On the permanent life of tissues outside of the organism[J].J Exp Med,1912,15(5):516-528.
17 Hoffman R.Histoculture and the immunodeficient mouse come to the cancer clinic-rational approaches to individualizing cancer-therapy and new drug-evaluation(review)[J].Int J Oncol,1992,1(4):467-474.
18 Delyon J,Varna M,Feugeas JP,et al.Validation of a preclinical model for assessment of drug efficacy in melanoma[J].Oncotarget,2016,7(11):13069-13081.
19 Colangelo D,Guo HY,Connors KM,et al.Noncolorimetric measurement of cell activity in three-dimensional histoculture using the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide:the pixel image analysis of formazan crystals[J].Anal Biochem,1992,205(1):8-13.
20 Plumb JA.Cell sensitivity assays:the MTT assay[J].Methods Mol Biol,2011,731(88):237-245.
21 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
22 Yoshimasu T,Oura S,Hirai I,et al.Data acquisition for the histoculture drug response assay in lung cancer[J].J Thorac Cardiovasc Surg,2007,133(2):303-308.
23 高隆,霍润辉.肺癌体外药敏试验与临床疗效的相关性[J].医学争鸣,2003,24(23):2203-2205.
24 Yoshimasu T,Ohta F,Oura S,et al.Histoculture drug response assay for gefitinib in non-small-cell lung cancer[J].Gen Thorac Cardiovasc Surg,2009,57(3):138-143.
25 Yoon YS,Kim CW,Roh SA,et al.Development and applicability of integrative tumor response assays for metastatic colorectal cancer[J].Anticancer Res,2017,37(3):1297-1303.
26 Hamashima C.Current issues and future perspectives of gastric cancer screening[J].World J Gastroenterol,2014,20(38):13767-13774.
27 Hoffman RM.The clinical benefit of the histoculture drug response assay[J].Gan To Kagaku Ryoho,2000,27(7):321-322.
28 曲爱兵.恶性肿瘤体外药敏试验方法[J].实用肿瘤学杂志,2001,15(3):238-239.
29 Mehren MV.The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors[J].Curr Opin Oncol,2008,20(4):428-432.
30 Fitzmaurice C,Dicker D,Pain A,et al.The global burden of cancer 2013 global burden of disease cancer collaboration[J].JAMA,2015,1(4):505-527.
31 Tanino H,Oura S,Hoffman RM,et al.Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay[J].Anticancer Res,2001,21(6A):4083-4086.
32 Lang J,Gao L,Guo Y,et al.Comprehensive treatment of squamous cell cancer of head and neck:Chinese expert consensus 2013[J].Future Oncol,2014,10(9):1635-1648.
33 Ho AS,Kraus DH,Ganly I,et al.Decision making in the management of recurrent head and neck cancer[J].Head Neck,2014,36(1):144-151.
34 Singh B,Li R,Xu L,et al.et al.Prediction of survival in patients with head and neck cancer using the histoculture drug response assay[J].Head Neck,2002,24(5):437-442.
35 Chan AT,Leung SF,Ngan RK,et al.Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma[J].J Natl Cancer Inst,2005,97(7):536-539.
36 Kanasugi M,Aoki D,Suzuki N,et al.Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer[J].Int J Gynecol Cancer,2006,16(1):409-415.
37 周辉良,鲁功成,罗义麒,等.组织培养药敏测试法在表浅膀胱肿瘤化疗药敏测试中的应用价值[J].临床泌尿外科杂志,2003,18(4):199-201.
38 Roife D,Kang Y,Li W,et al.Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy[J].Surgery,2017,161(5):1246-1254.
39 袁庶强,周志伟,梁永钜,等.三维培养药敏实验测定的结直肠癌化疗敏感性与多药耐药基因蛋白表达的关系[J].癌症,2009,28(9):932-938.

[1]	ZHANG Maoxiang,SUN Huixin,SONG Bingbing. Analysis of the incidence and mortality of malignant tumors in Daoli District,Harbin,2008—2012 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 261-265.
[2]	HAN Bangling,WANG Yimin,XUE Yingwei. Research progress in the relationship between neutrophils and malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 349-352.
[3]	ZHOU Jie, CHEN Yu, CHEN Daozhen. Application of nanoparticles in photodynamic therapy of tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 245-249.
[4]	HOU Siyu, CHEN Xiuwei. The structure and function of JMJD2B protein and its progress in the development of malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 250-253.
[5]	ZHANG Ting, HOU Guangying, WANG Xin, HE Yan. Research progress and clinical significance of QKI protein in malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 263-266.
[6]	LI Jing, ZHANG Yunyan. Research progress of miR-331-3p in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 125-129.
[7]	ZHANG Yongxin, HUANG He. Research progress and mechanism of Galectin-9 and various malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 159-163.
[8]	WU Yifei, LIU Baogang. Research progress of thioredoxin reductase 2 in malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 174-178.
[9]	HAN Xuejiao, LI Yanchun, SUN lichun, LU Hailing. Research progress of the relationship between 14-3-3ζ and malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 543-547.
[10]	HUO Mingjuan,MENG Xiangcheng,SUN Ying,CHENG Li. Research progress of ALCAM in gynecological malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 381-384.
[11]	HAO Lixiao,ZHANG Yunyan. Research progress of AIM2 in tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 175-178.
[12]	FAN Mingxv, ZHAO Yanbin, LI Boyang, WANG Yan. Research progress in the Notch pathway in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 57-60.
[13]	WANG Jijun,HE Yan. The research progresses in USP22 in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 551-554.
[14]	WANG Peng, WANG Zheng, ZHOU Zhixiang. Roles of p53 in the interaction with digestive malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 468-472.
[15]	SUN Zhi, CHEN Gongyan. The research progresses on RB1 in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 80-83.

Application of drug sensitivity from three-dimensional tissue in individualized precision medical treatment for tumor

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments